Impact of Continuous Venovenous Haemofiltration on Organ Failure During the Early Phase of Severe Sepsis

This study has been completed.
Sponsor:
Collaborator:
Ministry of Health, France
Information provided by:
Hopital Lariboisière
ClinicalTrials.gov Identifier:
NCT00406198
First received: November 30, 2006
Last updated: December 1, 2006
Last verified: November 2006
  Purpose

The impact of continuous veno-venous haemofiltration (CVVH) on sepsis-induced multiple organ failure severity is controversial. We thus sought to assess the effect of early application of haemofiltration on the degree of organ dysfunction and plasma cytokine levels in patients with severe sepsis or septic shock.


Condition Intervention Phase
Bacteremia
Gram-Negative Bacterial Infections
Gram-Positive Bacterial Infections
Pneumonia, Bacterial
Shock, Septic
Sepsis
Procedure: venovenous hemofiltration
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Supportive Care
Official Title: Phase 4 Randomized Multicentric Controlled Study on Impact of Continuous Venovenous Hemofiltration on Organ Failure at the Early Phase of Severe Sepsis

Resource links provided by NLM:


Further study details as provided by Hopital Lariboisière:

Primary Outcome Measures:
  • The primary end-point was the number, severity and duration of organ failures at 14 days, as evaluated by the SOFA score, on an intention-to-treat analysis

Secondary Outcome Measures:
  • Secondary end point : safety, ventilation and hemodynamic support weaning

Estimated Enrollment: 400
Study Start Date: March 1997
Estimated Study Completion Date: December 1999
Detailed Description:

prospective, randomized, open, multicentre study was performed between 1997 and 1999 in 16 French intensive care units. Patients were enrolled within 24 hours of development of the first organ failure related to a new septic insult. They were randomized to group 1 (HF), who received haemofiltration for a 96 hr period, or group 2 (C) who were managed conventionally. The primary end-point was the number, severity and duration of organ failures at 14 days, as evaluated by the SOFA score, on an intention-to-treat analysis. Strict guidelines were provided to perform continuous haemofiltration under the same conditions and objectives in all centres.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • clinically identified focus of infection associated with at least 2 SIRS criteria and one or more sepsis-induced organ failures within the 24 hours prior to inclusion, plus a SAPS II score between 35-63

Exclusion Criteria:

  • Patients were excluded if pregnant, younger than 18 years, in a moribund state, in chronic renal failure, or receiving immunosuppressive therapy.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00406198

Locations
France
Lariboisiere University Hospital
Paris, France
Sponsors and Collaborators
Hopital Lariboisière
Ministry of Health, France
Investigators
Principal Investigator: Didier Payen, MD, PhD Hpopital Lariboisiere
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00406198     History of Changes
Other Study ID Numbers: DP 97 02 06, ministère recherche EA 322
Study First Received: November 30, 2006
Last Updated: December 1, 2006
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Keywords provided by Hopital Lariboisière:
Sepsis syndrom
severe sepsis
septic shock
hemofiltration
multiple organ failure

Additional relevant MeSH terms:
Bacteremia
Bacterial Infections
Pneumonia, Bacterial
Pneumonia
Sepsis
Toxemia
Shock
Shock, Septic
Gram-Negative Bacterial Infections
Gram-Positive Bacterial Infections
Infection
Systemic Inflammatory Response Syndrome
Inflammation
Pathologic Processes
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections

ClinicalTrials.gov processed this record on April 17, 2014